← Back to all trials
Active Not Recruiting
NCT05030441
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
Conditions: Clonal Cytopenia of Undetermined Significance
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 20
Sponsor: Washington University School of Medicine
Location: Washington University School of Medicine St Louis Missouri
Summary
This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood count abnormalities in these patients.
The study will also be offered in a decentralized, remote structure to patients.
Eligibility Criteria
Inclusion Criteria:
* Unexplained cytopenia for at least 6 months. Cytopenia is defined as the presence of ≥1 blood count indexes below the following thresholds:
* Hgb \
Source: ClinicalTrials.gov (NCT05030441). StuddyBuddy aggregates publicly available trial information.
